Case report: combination of immune-related thrombocytopenia and myocarditis in а patient treated with immune checkpoint inhibitors for non‑small cell lung cancer
https://doi.org/10.18027/2224-5057-2023-13-1-24-29
Abstract
Immune-related adverse events (irAE) present a unique challenge in modern oncology. In patient treated with immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4, anti-PD-L1) for solid tumors irAEs rate ranges from 60 to 85 % [1]. irAEs lead to complete treatment discontinuation in approximately 40 % of patients [2]. The most common irAEs are endocrinopathies (up to 10 %), pneumonitis (5 to 10 %), autoimmune hepatitis (up to 20 %), colitis (up to 30 %), and skin toxicity (up to 50 %) [3]. Other forms of adverse events, such as hematologic and cardiovascular toxicities, are very rarely reported. We present a clinical case of two rare adverse events in a patient treated with pembrolizumab for PD-L1‑positive advanced non-small cell lung cancer.
About the Authors
S. V. Yugay
Saint Petersburg Clinical Hospital
Russian Federation
Russian Federation
Sergey V. Yugay, oncologist
Saint Petersburg
К. V. Dehanova
A. I. Burnazyan Federal Medical Biophysical Center
Russian Federation
Russian Federation
Xenia V. Dehanova, clinical resident
Moscow
I. V. Rikov
Saint Petersburg Clinical Hospital; Saint Petersburg State University
Russian Federation
Russian Federation
Ivan V. Rikov, MD, PhD, Head of the Oncology DepartmentSaint Petersburg; Lecturer, Oncology
Department
Saint Petersburg
М. F. Balluzek
Saint Petersburg Clinical Hospital; Saint Petersburg State University
Russian Federation
Russian Federation
Marina F. Balluzek, MD, PhD, DSc, Professor, Deputy Physician-in-Chief for Medicine, Head of the Cardiology Department; Professor of the Therapy Department
Saint Petersburg
References
1. Hryniewicki, A. T., Wang, C., Shatsky, R. A., & Coyne, C. J. (2018). Management of Immune Checkpoint Inhibitor Toxicities : A Review and Clinical Guideline for Emergency Physicians. Journal of Emergency Medicine, 55 (4), 489–502. https://doi.org/10.1016/j.jemermed.2018.07.005.
2. Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, (2017). Management of toxicities from immunotherapy : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 28 (Supplement 4), iv119–iv142. https://doi.org/10.1093/annonc/mdx225.
3. Gürdoğan M, Yalta K. Myocarditis associated with immune checkpoint inhibitors : Practical considerations in diagnosis and management. Anatol J Cardiol. 2020 ; 24 (2) : 68–75. doi:10.14744/AnatolJCardiol.2020.
4. Zhang L., Awadalla M., Mahmood S.S., Nohria A., Hassan M.Z.O., Thuny F., et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020 ; 41 : 1733–43.
5. Brahmer J.R., Lacchetti C., Schneider B.J., et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy : American Society of Clinical Oncology Clinical Practice Guideline. National Comprehensive Cancer Network. J ClinOncol. 2018 Jun 10 ; 36 (17) : 1714–1768.
6. Ahmad, S., Lewis, M., Corrie, P., &Iddawela, M. (2012). Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma. Journal of Oncology Pharmacy Practice, 18 (2), 287–292. https://doi.org/10.1177/107815521141100.
7. Le Roy, A., Kempf, E., Ackermann, F., Routier, E., Robert, C., Turpin, A., Marabelle, A., Mateus, C., Michot, J. M., &Lambotte, O. (2016). Two cases of immune thrombocytopenia associated with pembrolizumab. European Journal of Cancer, 54 (August 2014), 172–174. https://doi.org/10.1016/j.ejca.2015.10.073.
8. Mouri, A., Kaira, K., Shiono, A., Miura, Y., &Kagamu, H. (2020). Severe Thrombocytopenia Associated with Pembrolizumab in Patients with Non-small Cell Lung Cancer (NSCLC) : A case report and literature review. In Vivo, 34 (2), 877–880. https://doi.org/10.21873/invivo.11852.
9. Song, P., & Zhang, L. (2019). Eltrombopag treatment for severe refractory thrombocytopenia caused by pembrolizumab. European Journal of Cancer, 121, 4–6. https://doi.org/10.1016/j.ejca.2019.08.003.
10. Shiuan, E., Beckermann, K. E., Ozgun, A., Kelly, C., McKean, M., McQuade, J., Thompson, M. A., Puzanov, I., Greer, J. P., Rapisuwon, S., Postow, M., Davies, M. A., Eroglu, Z., & Johnson, D. (2017). Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. Journal for ImmunoTherapy of Cancer, 5 (1), 4–9. https://doi.org/10.1186/s40425-017-0210-0.
11. Chaturvedi, S., Arnold, D. M., & McCrae, K. R. (2018). Splenectomy for immune thrombocytopenia : Down but not out. Blood, 131 (11), 1172–1182. https://doi.org/10.1182/blood-2017-09-74235311.
12. Neunert, C., Lim, W., Crowther, M., Cohen, A., Solberg, L., &Crowther, M. A. (2011). The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood, 117 (16), 4190–4207. https://doi.org/10.1182/blood-2010-08-302984.
13. Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., Becker, J. R., Slosky, D. A., Phillips, E. J., Pilkinton, M. A., Craig-Owens, L ., Kola, N., Plautz, G., Reshef, D. S., Deutsch, J. S., Moslehi, J. J. (2016). Fulminant Myocarditis with Combination Immune Checkpoint Blockade. New England Journal of Medicine, 375 (18), 1749–1755. https://doi.org/10.1056/nejmoa1609214.
14. Tawbi, H. A., Forsyth, P. A., Algazi, A., Hamid, O., Hodi, F. S., Moschos, S. J., Khushalani, N. I., Lewis, K., Lao, C. D., Postow, M. A., Atkins, M. B., Ernstoff, M. S., Reardon, D. A., Puzanov, I., Kudchadkar, R. R., Thomas, R. P., Tarhini, A., Pavlick, A. C., Jiang, J., Margolin, K. (2018). Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. New Eng J Med, 379 (8), 722–730. https://doi.org/10.1056/nejmoa1805453.
15. Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., Friedlander, P. A., Kluger, H. M., Kohrt, H. E., Lundgren, L ., Margolin, K., Mitchell, A., Olencki, T., Pardoll, D. M., Reddy, S. A., … Cheever, M. A. (2016). PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. New Engl J Med, 374 (26), 2542–2552. https://doi.org/10.1056/nejmoa1603702.
16. Zhang L., Awadalla M., Mahmood S.S., Nohria A., Hassan M.Z.O., Thuny F., et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020 ; 41 : 1733–43
Review
For citations:
Yugay S.V., Dehanova К.V., Rikov I.V., Balluzek М.F. Case report: combination of immune-related thrombocytopenia and myocarditis in а patient treated with immune checkpoint inhibitors for non‑small cell lung cancer. Malignant tumours. 2023;13(1):24-29. (In Russ.) https://doi.org/10.18027/2224-5057-2023-13-1-24-29
Views:
652
Email this article 